Korro Bio, Inc (KRRO) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Korro Bio, Inc stock $7.95, price $12.71, that is 37.5% below the price, quality 25 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Korro Bio, Inc
KRRO · USFar too expensive (fair value 38% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $5.28 – $398.00 · fair‑value band $5.96 – $9.94 · the $12.71 price screens above the $7.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Korro Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Show moreShow less
The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Stock analysis
Korro Bio, Inc (KRRO) currently trades at $12.71, while our estimate is $7.95, 38% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $5.96 (bear) to $9.94 (bull), the price of $12.71 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Korro Bio, Inc reported revenue of $6.4M in FY2025 versus $14.1M in FY2021, a compound −17.9%/yr. Reported net income was −$117M in FY2025.
Key figures
Market cap $224M Micro · EPS (TTM) $−8.89 · Return on equity −113% · Return on assets (EBIT) −56.2% (5-year average) · Operating margin −5,891% · Revenue growth (YoY) −43.1% · Free cash flow −$79.1M · Net debt $21.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 141% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −38%, KRRO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 6 officers or directors sold shares worth $6.7M and none bought.
- SaleJean Francois FormelaDirector8× since May 28, 2026: 430,521 shares, avg. $14.25$6.1MNov 12, 202610b5-1 plan
- BuyLynx1 Capital Management LP10% owner2× since Aug 6, 2026: 86,493 shares, avg. $11.14$963,566Oct 26, 2026
- SaleOliver DolanSenior Vice President, Finance3× since Jun 16, 2026: 10,741 shares, avg. $12.67$136,046Sep 11, 2026
- SaleRam AiyarPresident and CEO, Director2× since May 29, 2026: 20,954 shares, avg. $12.39$259,567Aug 4, 2026
- SaleJeffrey CerioGeneral Counsel6,609 shares at $10.83$71,575Jun 16, 2026
- SaleLoic A VincentChief Scientific Officer3,418 shares at $10.83$37,017Jun 16, 2026
- SaleTodd ChappellChief Operating Officer3,168 shares at $10.83$34,309Jun 16, 2026
- BuyWeston Nichols10% owner520 shares at $10.60$5,512Mar 31, 2026
- BuyAnthony A. Florence Jr.10% owner207,100 shares at $11.11$2.3MMar 10, 2026
- BuyMohamad Makhzoumi10% owner207,100 shares at $11.11$2.3MMar 10, 2026
Plus 7 more entries from the last 12 months.
Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Korro Bio, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs KRRO |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs KRRO |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs KRRO |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs KRRO |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs KRRO |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs KRRO |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs KRRO |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs KRRO |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs KRRO |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs KRRO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Korro Bio, Inc (KRRO) overvalued or undervalued?
What is the fair value of KRRO?
What is the quality score of KRRO?
What is the price target for Korro Bio, Inc (KRRO)?
What is the Korro Bio, Inc stock forecast for 2026?
What is the intrinsic value of Korro Bio, Inc (KRRO)?
Is Korro Bio, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KRRO?
How much is Korro Bio, Inc worth?
What do the bullish and bearish scenarios say about KRRO?
How solid is the balance sheet of Korro Bio, Inc (KRRO)?
How far is KRRO from its 52-week high?
Which stocks are comparable to Korro Bio, Inc?
Is Korro Bio, Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Korro Bio, Inc (KRRO)?
What should I pay attention to with Korro Bio, Inc right now?
Key figures of Korro Bio, Inc
How large is the market capitalisation of Korro Bio, Inc (KRRO)?
What are the earnings per share of Korro Bio, Inc (KRRO)?
What is the return on equity of Korro Bio, Inc (KRRO)?
What is the EBIT return on assets of Korro Bio, Inc (KRRO)?
What is the operating margin of Korro Bio, Inc (KRRO)?
How fast is revenue growing at Korro Bio, Inc (KRRO)?
How much free cash flow does Korro Bio, Inc (KRRO) generate?
How much net debt does Korro Bio, Inc (KRRO) carry?
Watch Korro Bio, Inc in the live analysis
One click puts Korro Bio, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.